Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03563547
Other study ID # SoyfitKW01
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date September 3, 2009
Est. completion date October 9, 2017

Study information

Verified date June 2018
Source Austrian Academic Institute for Clinical Nutrition
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Familial hypercholesterolemia (FH) is an inheritable, autosomal dominant disorder leading to pathologically increased levels of low-density-lipoprotein cholesterol (LDL-C). Dietary treatment remains an important tool in the management of affected children even after the decision for the initiation of pharmacotherapy is made. However, little evidence is available on the beneficial effects of diets low in saturated fat and cholesterol and diets enriched with soy in children affected with FH. Based on these previous findings we hypothesize that the LDL-C lowering effect of a fat-modified diet could be further increased by the addition of soy-protein in children affected with HeFH.


Description:

This study is a prospective randomized controlled trial. The enrolled subjects were recruited from the outpatient clinic for disorders of metabolism of the Medical University of Vienna. Subjects were either allocated into a group treated with a dietary regimen high in unsaturated fats, low in saturated fats and enriched with soy-protein ("soy group") or a group treated with a diet high in unsaturated fats and low in saturated fats ("control group") alone at random. All subjects had been instructed to adhere to a fat-modified diet as described below prior to enrolment into the study as part of their routine treatment. Prior to being considered for inclusion in the study all subjects had to undergo nutritional protocoling using 24h dietary recall protocols, which were completed by their legal guardians, for 7 days. This was done to confirm adherence to the routine dietary treatment. Furthermore, all patients had been screened for metabolic diseases other than FH as part of their initial routine assessment in our specialised centre.

Subjects in both groups had been instructed to achieve specific daily maximum intakes in total fat (≤ 30% of total energy intake), saturated fatty acids (≤10% of total fat intake) and cholesterol (≤ 300 mg). Furthermore the participating families had been trained to replace as many visible fat sources as possible with rapeseed oil due to its favorable composition of polyunsaturated fatty acids.24 Subjects allocated to the soy group and their families were additionally instructed to consume at least 0.25 g of soy protein per kg bodyweight per day and were provided with recipes and practical advice on how to achieve this goal. Example provided: a child with a bodyweight of 30kg would have to consume the equivalent of approx. 50g of Tofu per day to meet the treatment target. This dosage had been reported as effective for LDL-C reduction in children in a previous, non-controlled study.10

Further appointments with an experienced dietitian were made after enrolment for both treatment groups, totalling 7 training sessions (60 minutes each) over the course of the first 7 weeks of the trial. This was done to identify possible issues with the practical implementation of especially the soy-enriched diet.

Patients were asked to provide weekly urine samples and blood was drawn immediately after enrolment, week 7 and week 13, respectively. The urine- and plasma samples were immediately frozen and later analysed for their isoflavone content. Isoflavone levels were assessed at baseline to verify that the respective patients did not consume soy products prior to the trial. All enrolled subjects had to participate for 13 weeks or were excluded from the statistical evaluation (per protocol analysis). If relevant levels of isoflavones were detected in either urine or plasma of subjects in the Control-group the subjects were to be excluded from any further statistical evaluation.

The study was approved by the Ethics Committee of the Medical University of Vienna. Informed consent from all participating subjects and their legal guardians was obtained prior to their enrolment in the study. Our research was conducted in accordance with the latest Declaration of Helsinki.


Recruitment information / eligibility

Status Completed
Enrollment 34
Est. completion date October 9, 2017
Est. primary completion date October 9, 2014
Accepts healthy volunteers No
Gender All
Age group 4 Years to 14 Years
Eligibility Inclusion Criteria:

- Informed consent of both the patient and their legal guardian, age of 4 to 14, diagnosis of definite FH using the Simon Broome criteria, body weight within normal age-specific percentile range (Kromeyer-Hauschild et al.), the proven ability and willingness to adhere to a fat-modified diet.

Exclusion Criteria:

- Metabolic or genetic disorders other than FH, current infectious disease, current or history of cancerous disease, current treatment with lipid lowering drugs, failure to complete all trial-related assessments, reported habit of consuming soy products or adherence to a non-standard diet (e.g. vegetarianism) prior to enrolment into the study.

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Dietary counseling (fat modifed diet)
Subjects in both groups had been instructed to achieve specific daily maximum intakes in total fat (= 30% of total energy intake), saturated fatty acids (=10% of total fat intake) and cholesterol (= 300 mg). Furthermore the participating families had been trained to replace as many visible fat sources as possible with rapeseed oil due to its favorable composition of polyunsaturated fatty acids.
Dietary Counseling (fat modified + soy enriched diet)
Subjects in both groups had been instructed to achieve specific daily maximum intakes in total fat (= 30% of total energy intake), saturated fatty acids (=10% of total fat intake) and cholesterol (= 300 mg). Furthermore the participating families had been trained to replace as many visible fat sources as possible with rapeseed oil due to its favorable composition of polyunsaturated fatty acids. Subjects allocated to the soy group and their families were additionally instructed to consume at least 0.25 g of soy protein per kg bodyweight per day and were provided with recipes and practical advice on how to achieve this goal. Example provided: a child with a bodyweight of 30kg would have to consume the equivalent of approx. 50g of Tofu per day to meet the treatment target.

Locations

Country Name City State
Austria Austrian Academic Institute for Clinical Nutrition Vienna

Sponsors (2)

Lead Sponsor Collaborator
Austrian Academic Institute for Clinical Nutrition Medical University of Vienna

Country where clinical trial is conducted

Austria, 

Outcome

Type Measure Description Time frame Safety issue
Primary LDL-C change from baseline 13 weeks
See also
  Status Clinical Trial Phase
Terminated NCT03694197 - Long Term Safety Study of PRALUENT Phase 4
Active, not recruiting NCT04759534 - Application of PCSK9 Inhibitors in Patients With Heterozygous Familial Hypercholesterolemia Phase 3
Completed NCT01968980 - A 52 Week Study To Assess The Use Of Bococizumab (PF-04950615; RN316) In Subjects With Heterozygous Familial Hypercholesterolemia Phase 3
Completed NCT00171236 - Efficacy and Safety of Fluvastatin in Children With Heterozygous Familial Hypercholesterolemia Phase 3
Completed NCT03397121 - Trial to Evaluate the Effect of Inclisiran Treatment on Low Density Lipoprotein Cholesterol (LDL-C) in Subjects With Heterozygous Familial Hypercholesterolemia (HeFH) Phase 3
Completed NCT04173793 - A Study of PCSK9 Inhibitor AK102 in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) Phase 2
Not yet recruiting NCT06164730 - A Study of VERVE-102 in Patients With Familial Hypercholesterolemia or Premature Coronary Artery Disease Phase 1
Completed NCT02326220 - Study of Alirocumab (REGN727/SAR236553) in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) Undergoing Low-density Lipoprotein (LDL) Apheresis Therapy Phase 3
Completed NCT02392559 - Trial Assessing Efficacy, Safety and Tolerability of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition in Paediatric Subjects With Genetic Low-Density Lipoprotein (LDL) Disorders Phase 3
Completed NCT02460159 - A Clinical Trial to Assess the Long Term Safety and Tolerability of MK-0653C in Japanese Participants With Hypercholesterolemia (MK-0653C-384) Phase 3
Terminated NCT01583647 - A Study of Extended-release (ER) Niacin/Laropiprant in Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0524A-158) Phase 1
Active, not recruiting NCT05398029 - A Study of VERVE-101 in Patients With Familial Hypercholesterolemia and Cardiovascular Disease Phase 1
Completed NCT00706849 - Efficacy and Safety Study of ISIS 301012 (Mipomersen) as Add-on in Familial Hypercholesterolemic Patients With Coronary Artery Disease Phase 3
Completed NCT04666298 - Study of Efficacy and Safety of Inclisiran in Japanese Participants With High Cardiovascular Risk and Elevated LDL-C Phase 2
Completed NCT01515241 - Exploratory Study of Plaque Regression Phase 2
Completed NCT03038022 - Study of MGL-3196 in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) Phase 2
Completed NCT01576484 - Open-Label Extension of Study R727-CL-1003 (NCT01266876) to Evaluate the Long-Term Safety and Efficacy of Alirocumab (REGN727) in Participants With Heterozygous Familial Hypercholesterolemia (HeFH) Phase 2
Terminated NCT00151788 - Efficacy and Safety of the ACAT Inhibitor CS-505 (Pactimibe) for Reducing the Progression of Carotid Artery Disease. This Study is Also Known as CAPTIVATE. Phase 2/Phase 3
Completed NCT05325203 - A Study to Evaluate the Efficacy and Safety of JS002 in Patients With Heterozygous Familial Hypercholesterolemia (HeFH). Phase 3
Completed NCT01709500 - Study of Alirocumab (REGN727/SAR236553) in Patients With heFH (Heterozygous Familial Hypercholesterolemia) Who Are Not Adequately Controlled With Their LMT (Lipid-Modifying Therapy) Phase 3